Linked Life Data

21055801

Source:http://linkedlifedata.com/resource/pubmed/id/21055801

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9752
pubmed:dateCreated
2010-11-15
pubmed:databankReference
pubmed:abstractText
Despite treatment with renin–angiotensin–aldosterone system (RAAS) inhibitors, patients with diabetes have increased risk of progressive renal failure that correlates with albuminuria. We aimed to assess whether paricalcitol could be used to reduce albuminuria in patients with diabetic nephropathy.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1474-547X
pubmed:author
pubmed:issnType
Electronic
pubmed:day
6
pubmed:volume
376
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1543-51
pubmed:dateRevised
2011-3-15
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
pubmed:affiliation
University Medical Centre Groningen, University of Groningen, Groningen, Netherlands. d.de.zeeuw@med.umcg.nl
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study